Demonstrates inhibition of OSCC progression in vitro and in vivo, suggesting DPSC-IVs as a novel therapeutic option.
Oral squamous cell carcinoma (OSCC) represents a globally predominant type of oral malignancy with escalating incidence, featuring aggressive biological behaviour, prominent metastatic potential and poor clinical outcomes. Emerging evidence positions dental pulp stem cell-sourced intracellular vesicles (DPSC-IVs) as novel therapeutic vectors in regenerative oncology, citing their low immunogenicity, favourable safety profile and ability to modulate tumour microenvironment. In this study, DPSC-IVs significantly inhibited OSCC progression both in vitro and in vivo, suppressing tumour cell proliferation, invasion and colony formation while simultaneously promoting apoptosis. Notably, the antitumor effect of DPSC-IVs was further enhanced by combining them with autophagy inhibitor 3-methyladenine (3-MA), which synergistically suppressed the PI3K/AKT/mTOR pathway and enhanced mitochondrial stress while suppressing residual cytoprotective autophagy. Mechanistically, DPSC-IVs served as carriers of PTEN into OSCC cells, which in turn suppressed oncogenic PI3K/AKT signalling and induced excessive mitophagy. Taken together, this study indicated that DPSC-IVs could suppress OSCC through dual mechanisms, highlighting their potential as a promising and clinically translatable therapeutic option with advantages in safety and scalable production.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: